Zymeworks (ZYME) financial statements
Zymeworks reported revenue of $106M in fiscal 2025, up 22.2% a year over 5 years.
Net income was -$81M and the operating margin -87.3%, against -481.3% in 2020.
Free cash flow was -$35M, and the company returned $42M in net buybacks.
The diluted share count rose 50% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Zymeworks's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $39M | $27M | $412M | $76M | $76M | $106M |
| Research and development | $171M | $200M | $209M | $144M | $135M | $137M |
| Selling, general and admin | $55M | $43M | $73M | $70M | $62M | $62M |
| Operating income | -$187M | -$216M | $131M | -$138M | -$137M | -$93M |
| Pre-tax income | -$180M | -$212M | $135M | -$119M | -$117M | -$80M |
| Income tax | $429,000 | -$516,000 | $11M | -$568,000 | $6M | $1M |
| Net income | -$181M | -$212M | $124M | -$119M | -$123M | -$81M |
| EPS (diluted) | -$3.58 | -$4.61 | $1.90 | -$1.72 | -$1.62 | -$1.08 |
| Diluted shares | 50M | 52M | 65M | 69M | 76M | 75M |
| Operating margin | -481.3% | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Net margin | -463.5% | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
Balance sheet
Fiscal years, from Zymeworks's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $242M | $253M | $492M | $374M | $66M | $41M |
| Receivables | — | $16M | $33M | $19M | $56M | $5M |
| Total current assets | — | $288M | $545M | $413M | $300M | $249M |
| Property, plant and equipment | — | $23M | $25M | $20M | $18M | $16M |
| Goodwill | — | $12M | $12M | $12M | $12M | $12M |
| Total assets | — | $389M | $649M | $581M | $463M | $347M |
| Total current liabilities | — | $72M | $96M | $56M | $88M | $42M |
| Total liabilities | — | $140M | $156M | $116M | $124M | $78M |
| Shareholders' equity | $410M | $249M | $493M | $465M | $339M | $269M |
| Net debt | -$242M | -$202M | -$401M | -$158M | -$66M | -$41M |
Cash flow
Fiscal years, from Zymeworks's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$151M | -$192M | $144M | -$118M | -$110M | -$33M |
| Capital spending | $4M | $12M | $8M | $2M | $2M | $2M |
| Free cash flow | -$156M | -$205M | $136M | -$121M | -$112M | -$35M |
| Stock-based compensation | $29M | $11M | $4M | $8M | $18M | $28M |
| Share buybacks (net) | — | — | $0 | $0 | -$30M | -$42M |
| Free cash flow margin | -399.8% | -767.8% | 33.0% | -158.9% | -146.8% | -32.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ZYME.
Open ZYME in InvestinglyQuestions
What was Zymeworks's revenue in 2025?
$106M in fiscal 2025, from its 10-K filing.
How much free cash flow does Zymeworks generate?
-$35M in fiscal 2025 (operating cash flow minus capital spending).
From Zymeworks's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.